excelleRx Completes a $37 Million Equity Investment Led by LLR Partners

PHILADELPHIA, PA, March 3, 2003 - LLR Partners Inc. ("LLR"), Wachovia Capital Partners ("Wachovia") and Primus Venture Partners ("Primus") today announced that they completed a $37 million equity investment in excelleRx, Inc. ("excelleRx" or the "Company"). excelleRx, headquartered in Philadelphia, is a leading medication management company providing prescription medication consultation and distribution services to the hospice industry and other niche markets. The $37 million capital infusion will be utilized to repurchase shares from certain non-management shareholders and to fund excelleRx's growth plans.

"We are pleased to welcome our new financial partners to excelleRx and for their support of our aggressive growth plans," said Calvin H. Knowlton the Chief Executive Officer of excelleRx, "We are excited by their endorsement of our business model and look forward to working with them as we continue to build the excelleRx franchise."

"We are extremely excited about our investment in excelleRx due to its extraordinary growth prospects, superior service offerings and experienced management team," noted Howard Ross, a Partner with LLR. "Since the Company's founding in 1996, excelleRx has grown to become the largest medication management company serving the hospice industry and we look forward to helping the Company as it continues growing its leading market position."

Wachovia and Primus also believe strongly in excelleRx's growth potential. "As the market leader in the hospice industry, excelleRx has significant opportunities to leverage their experience to other complementary markets," said Neal Morrison, a Partner of Wachovia. "excelleRx's ability to deliver to its customers a competitively-priced solution, exceptional access to information and the highest quality prescriptive care will drive continued growth," added Loyal Wilson, Managing Director at Primus.

About LLR Partners Inc. (LLR)
LLR Partners Inc. is a $260 million private equity firm providing capital to middle market companies with strong growth potential, proven business models and outstanding management teams. LLR primarily makes investments of $10 million to $25 million in a broad range of growth industries, with an emphasis on business services, healthcare and information technology. Based in Philadelphia, LLR focuses on creating value in superior investment situations in the Mid-Atlantic region. For more information about LLR, please visit www.llrpartners.com.

About Wachovia Capital Partners (Wachovia)
Wachovia Capital Partners with $1.2 billion of invested equity capital under management, is the principal investing arm of Wachovia Corp., the nation's fifth largest bank holding company. Wachovia Capital Partners targets equity and mezzanine investments of $10 to $50 million in the growth industrial, business services, financial services, media and communications, healthcare, and energy sectors. For more information on Wachovia Capital Partners, visit Wachovia Capital Partners' website at www.wachoviacapitalpartners.com.

About Primus Venture Partners (Primus)
Primus Venture Partners is a venture capital firm committed to funding private companies with exceptional growth potential. Primus currently manages $625 million of private equity capital across five funds and has invested in over 100 companies since its inception. Primus invests in companies at all stages of development, with a particular emphasis on growth capital financing, and concentrates on three industry groupings: business services and software; media and communications; and medical technology and healthcare services. The firm began investing in 1983 and works with entrepreneurs and management teams to build successful companies. Primus prefers investments in the $5 - $15 million range per company. For more information about Primus, please visit www.primusventure.com.

About excelleRx (excelleRx)
excelleRx, Inc. is a technology-based medication management company providing medication consultation and distribution services. The Company is the market-leader in hospice pharmaceutical care, currently serving over 250 hospice organizations and over 18,000 patients daily. excelleRx is also an emerging provider of medication care for the organ transplant and chronic pain markets. The Company's systems and technology are designed to optimize the use of medication therapy and stimulate evidence-based, predictive medication prescribing choices that improve documented patient outcomes. Through its two Pharmaceutical Care Support Centers in Philadelphia, PA and Tempe, AZ, excelleRx provides 24/7 access to over 80 pharmacists and technicians who provide expert pharmaceutical care consultation established in conjunction with the patient's prescriber and primary nurse. The Company also operates two central prescription-processing centers in Philadelphia, PA and Memphis, TN that fill and ship over 7,000 prescriptions daily.

Principals of Fairmount Partners acted as advisors to excelleRx, Inc. in this transaction.

Contact:

Richard W. Thatcher, Jr. and David K. Reed